Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Calgary
$120,000.00
Investigating the role and function of type 2 innate lymphoid cells during PD-1 blockade
EF 2024-25
Résumé
Our immune system is comprised of a diverse network of white blood cells. Within this network, specialised populations such as T cells are employed to fight infection and cancer. T cells carry what are known as immune checkpoint proteins, natural brakes that dampen their capacity to eliminate pathogens and tumours. PD-1 is one such protein present on the surface of T cells, suppressing their activity. Using drugs to block PD-1 restores the ability of the patient's own T cells to kill cancer cells. Although efficient in a variety of cancers, many patients unfortunately do not respond to these treatments. Our recent work suggests that in addition to T cells, a rare white blood cell population called type 2 innate lymphoid cells (ILC2s) carry PD-1 on their surface. Interestingly, the function of ILC2s is also dampened by PD-1. Despite their relatively low abundance compared to T cells, ILC2s provide crucial signals that shape the immune response in their respective environments. We believe that ILC2s may be important communicators, providing anti-tumour signals to other white blood cells in the tumour environment during PD-1 blockade therapy. Building on our foundation, my project will investigate the role and function of ILC2s during PD-1 blockade. By studying animal models, I will examine how the blockade of PD-1 impacts the function of ILC2s in tumours, and determine whether ILC2s contribute to overall anti-tumour responses and treatment efficacy. This project will pave the way for future studies exploring the potential of ILC2s in novel precision cancer medicines. Ultimately, my goal is to harmonise the intricate mechanisms of different white blood cells in our body, to ensure that we have better ways to improve patient outcomes and the lives of people in Canada.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518117
Name
Seo Hobin
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the role and function of type 2 innate lymphoid cells during PD-1 blockade
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Animal Models; Canadian Cancer Research; Cancer Immunology; Immune Checkpoint Blockade; Immunotherapy; Innate And Adaptive Immunity; Novel Cancer Therapies; Pd-1; Spectral Flow Cytometry; Type 2 Innate Lmyphoid Cells
Abstract
Our immune system is comprised of a diverse network of white blood cells. Within this network, specialised populations such as T cells are employed to fight infection and cancer. T cells carry what are known as immune checkpoint proteins, natural brakes that dampen their capacity to eliminate pathogens and tumours. PD-1 is one such protein present on the surface of T cells, suppressing their activity. Using drugs to block PD-1 restores the ability of the patient's own T cells to kill cancer cells. Although efficient in a variety of cancers, many patients unfortunately do not respond to these treatments. Our recent work suggests that in addition to T cells, a rare white blood cell population called type 2 innate lymphoid cells (ILC2s) carry PD-1 on their surface. Interestingly, the function of ILC2s is also dampened by PD-1. Despite their relatively low abundance compared to T cells, ILC2s provide crucial signals that shape the immune response in their respective environments. We believe that ILC2s may be important communicators, providing anti-tumour signals to other white blood cells in the tumour environment during PD-1 blockade therapy. Building on our foundation, my project will investigate the role and function of ILC2s during PD-1 blockade. By studying animal models, I will examine how the blockade of PD-1 impacts the function of ILC2s in tumours, and determine whether ILC2s contribute to overall anti-tumour responses and treatment efficacy. This project will pave the way for future studies exploring the potential of ILC2s in novel precision cancer medicines. Ultimately, my goal is to harmonise the intricate mechanisms of different white blood cells in our body, to ensure that we have better ways to improve patient outcomes and the lives of people in Canada.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Seo, Hobin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~